The role of topical calcineurin inhibitors in atopic dermatitis.
about
Downregulation of immunological mediators in 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions by hydrocortisone-loaded chitosan nanoparticlesEfficient immuno-modulation of TH1/TH2 biomarkers in 2,4-dinitrofluorobenzene-induced atopic dermatitis: nanocarrier-mediated transcutaneous co-delivery of anti-inflammatory and antioxidant drugs.Recent developments in the treatment of adult atopic dermatitis.Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.Pimecrolimus for psoriasis.Suppression of skin inflammation in keratinocytes and acute/chronic disease models by caffeic acid phenethyl ester.New treatment strategy and assessment questionnaire for external auditory canal pruritus: topical pimecrolimus therapy and Modified Itch Severity Scale.Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National HealTreatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus.Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis.Guidelines for treatment of atopic eczema (atopic dermatitis) part I.[Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].Tacrolimus: a new option in therapy-resistant chronic external otitis.
P2860
Q34488981-A6DDAB8A-55AE-4D67-B108-90BD252F5CDFQ34514774-F4761F69-418C-4BB0-B91B-07053878E93EQ36459429-9DCAE4D5-C934-4094-94ED-47E722A57630Q36681795-C4C3174D-CDEE-44E5-9E6F-2267D6C9BBB3Q36940038-1DAD74EE-5A4A-40C3-9D3B-84FFF8CA00F6Q37634944-12E251BC-0B08-4AA4-B3F1-4D33593D1303Q38086585-2B6537CF-5647-4A77-AE22-A6432D9CF361Q38929252-18A7DB94-C41F-4C66-A5A9-72DC75373E2DQ43239478-C37025F8-5F60-475D-AFEB-791633234F3DQ44513075-0A8A9C68-63DF-4334-927B-F16ABFE73378Q46491594-14D7880B-CDEA-40BD-9A95-AD99930C957FQ46970175-25DB9A37-DAF1-46BC-905E-D484A6EED017Q50927518-A2A16909-85F2-4B3E-8635-46CEF07240B8Q52767173-6CAD5B40-206A-4AA8-B27B-FDEB5AEAFA20Q52926520-1630F842-A56A-4543-8D07-5BEF3A45709C
P2860
The role of topical calcineurin inhibitors in atopic dermatitis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The role of topical calcineurin inhibitors in atopic dermatitis.
@ast
The role of topical calcineurin inhibitors in atopic dermatitis.
@en
type
label
The role of topical calcineurin inhibitors in atopic dermatitis.
@ast
The role of topical calcineurin inhibitors in atopic dermatitis.
@en
prefLabel
The role of topical calcineurin inhibitors in atopic dermatitis.
@ast
The role of topical calcineurin inhibitors in atopic dermatitis.
@en
P2093
P2860
P1476
The role of topical calcineurin inhibitors in atopic dermatitis.
@en
P2093
A Giannetti
European Working Group on Atopic Dermatitis
J Berth-Jones
J-F Stalder
K Thestrup-Pedersen
P2860
P356
10.1111/J.1365-2133.2004.06269.X
P407
P478
151 Suppl 70 Dec 2004
P577
2004-12-01T00:00:00Z